Real-world data collected from a registry can be used to reliably compare the effectiveness of different multiple sclerosis (MS) treatments, so long as appropriate methodologies are employed to account for the messiness — what researchers call confounding bias — of real-world data, according to a new study. While registries…

The European Union (EU) is providing 7.1 million euros (about $7.6 million) over five years to a global interdisciplinary consortium that seeks to identify the causes of multiple sclerosis (MS) — with a particular focus on viruses — and find new treatments for the disease. The “BEHIND MS”…

Heligenics has discovered a number of variations in the interferon beta 1 (IFNB1) gene that may markedly improve the effectiveness of medications containing the interferon beta protein — a protein widely used in the treatment of multiple sclerosis (MS). The discovery was made using the biotechnology company’s…

Note: This column describes the author’s own experiences with several disease-modifying therapies for multiple sclerosis. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. Times, they’ve been a-changing for disease-modifying therapies (DMTs). When I was diagnosed with multiple…

Note: This column describes the author’s own experiences with Ocrevus (ocrelizumab). Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. Tomorrow morning, I’ll have my 13th infusion of Ocrevus (ocrelizumab). I’ve been approved for the fast infusion rate, so…

Biogen has been a top dog in the multiple sclerosis (MS) treatment field for decades. The pharmaceutical giant developed Avonex (interferon beta-1a), approved in the U.S. in 1996 as one of the first disease-modifying therapies (DMTs) for MS. I remember how excited I was to be…

In evaluating potential treatments for multiple sclerosis (MS) over the past two decades, England’s National Institute for Health and Care Excellence (NICE) made differing assumptions about whether and how the therapies’ effects will diminish over time. Such assumptions have a significant impact in estimating a therapy’s cost-effectiveness — a…

About 10%-20% of people with multiple sclerosis (MS) receive baclofen to control their spasticity, but up to half of patients stop the medication in the first six months, a large Swedish population-based study shows. The high rates of discontinuation suggest baclofen has “a low success rate of…

Genetic variants in genes mostly active in the brain and spinal cord — the central nervous system — are associated with the severity of multiple sclerosis (MS), and linked to a faster accrual of disability and greater signs of brain tissue damage, a new study found. Importantly, researchers estimated…

The newest recipients of the MS Australia incubator grants will seek novel ways to prevent and treat multiple sclerosis (MS) and explore the prevalence and incidence of the neurodegenerative disorder in different parts of the country. One scientist will use the funding to explore disease risk factors — and…

Innovative Trials has selected the MS Society UK as its charity partner for the next year, and intends to raise at least £3,000 (about $3,600) to support multiple sclerosis (MS) research and the society’s quest for a world without MS. Innovative Trials works with pharmaceutical companies and…

In this installment of our “Expert Voices” series, Multiple Sclerosis News Today asked Allen C. Bowling, MD, PhD, to answer some of your questions related to complementary and alternative medicine (CAM) for people with multiple sclerosis (MS). Bowling is an internationally recognized neurologist and integrative medicine pioneer with…

  There are more than a dozen disease-modifying therapies available to treat MS. Some are shots, some are infusions, and some are pills. Some are more effective than others. The marketing intelligence company Spherix Global Insights regularly surveys which of these treatments are being used by neurologists and…

What does your neurologist consider when he or she is deciding how best to treat your multiple sclerosis? A recent report from Spherix Global Insights, a business intelligence and market research company that looks at drug trends every quarter, sheds some light on that. In my…

I’ve been taking a statin drug for years to keep my cholesterol low, and it’s doing a really good job. Now, there’s hope that this class of drug also might be useful for MS patients. A major trial in the U.K. is testing the drug simvastatin (used to control…